抗线粒体M2抗体与肌炎心脏受累及免疫介导炎症性肌病样病理相关
该研究基于北京协和医院2008至2020年住院的987例特发性炎症性肌病(IIM)患者的前瞻性队列,发现55例(6%)AMA-M2阳性。AMA-M2阳性患者心脏受累率显著更高(60% vs 12.9%,P<0.001),且AMA-M2阳性是心脏受累的独立危险因素(HR 3.156,P<0.001),但长期生存无差异。
要点
- AMA-M2阳性IIM患者心脏受累率高达60%,显著高于阴性患者的12.9%。
- AMA-M2阳性是心脏受累的独立危险因素(HR 3.156,P<0.001)。
- AMA-M2阳性与阴性患者长期生存无显著差异(P=0.86)。
核心结论
- AMA-M2阳性定义了一个具有显著心脏受累和免疫介导炎症性肌病组织学特征的IIM亚组,但不一定预后更差。
研究设计与样本
- 历史前瞻性队列研究,纳入北京协和医院2008至2020年住院的987例IIM患者,通过PROMIS注册前瞻性收集结局。
主要发现
- 987例IIM患者中55例(6%)为AMA-M2阳性。
- AMA-M2阳性患者多发性肌炎(PM)比例更高(56% vs 23.5%,P<0.001)。
- AMA-M2阳性患者基线γ-谷氨酰转移酶(78.0 vs 35.0,P<0.001)和碱性磷酸酶(85.0 vs 64.0,P<0.001)更高。
- AMA-M2阳性患者心脏受累率显著更高(60% vs 12.9%,P<0.001),其中心律失常56%、心力衰竭44%、肺动脉高压31%。
- 多因素Cox分析显示AMA-M2阳性是心脏受累的独立危险因素(HR 3.156,P<0.001);两组长期生存无差异(平均生存103.9个月 vs 98.0个月,P=0.86)。
关键数值与推荐
- AMA-M2阳性患者心脏受累率60%(vs 12.9%,P<0.001),其中心律失常56%、心力衰竭44%、肺动脉高压31%。
- AMA-M2阳性是心脏受累的独立危险因素,HR 3.156(P<0.001)。
- 部分肌肉活检显示免疫介导坏死性肌病特征,心脏活检示结构变性伴轻微炎症,肝活检证实早期原发性胆汁性胆管炎(PBC)。
临床怎么用
- 对IIM患者应检测AMA-M2以识别心脏受累高风险亚组,并加强心脏监测与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Cardiac involvement in idiopathic inflammatory myopathies (IIM) is rare but potentially severe. Anti-mitochondrial M2 antibody (AMA-M2) has been implicated in cardiac involvement, but the association remains underexplored. This study aims to evaluate the clinical, pathological and prognostic features of AMA-M2 IIM. METHODS: This historic prospective cohort included IIM patients hospitalized at Peking Union Medical College Hospital between 2008 and 2020. Outcomes were prospectively collected through the Prospective Registry Of MyositIS (PROMIS) registry. Cox regression models were employed to identify risk factors of cardiac involvement and mortality. RESULTS: Among 987 IIM patients, 55 (6%) were AMA-M2 positive. These patients exhibited higher rates of PM (56% vs 23.5%, P < 0.001), and elevated baseline gamma-glutamyl transferase (78.0 vs 35.0, P < 0.001) and alkaline phosphatase (85.0 vs 64.0, P < 0.001). Throughout disease courses, AMA-M2-positive patients had significantly higher rates of cardiac involvement (60% vs 12.9%, P < 0.001), including arrhythmias (56%), heart failure (44%) and pulmonary hypertension (31%). Some of the muscle biopsies showed features consistent with immune-mediated necrotizing myopathy, cardiac biopsies demonstrating structural degeneration with minimal inflammation and liver biopsies confirming early-stage primary biliary cholangitis (PBC). Multivariate Cox analysis identified AMA-M2 positivity as an independent risk factor for cardiac involvement (hazard ratio 3.156, P < 0.001). Despite frequent cardiac manifestations, long-term survival did not differ between AMA-M2-positive and -negative patients (mean survival: 103.9 months vs 98.0 months, P = 0.86). CONCLUSION: AMA-M2 positivity defines an IIM subgroup with significant cardiac involvement and an immune-mediated inflammatory muscle histology, but not necessarily worse long-term survival. These findings highlight the need for early recognition and tailored management of AMA-M2 IIM.
引用
- Pang Y, Zhang L, Yao C, et al. Anti-mitochondrial M2 antibody links to cardiac involvement and immune-mediated inflammatory myopathy-like pathology in myositis. Rheumatology (Oxford). 2026. PMID: 41485097. doi:10.1093/rheumatology/keaf670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。